Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar- tocilizumab) to Treat Moderate to Severe Rheumatoid Arthritis
Shots:
- Bio-Thera to receive $30M up front following the achievement of P-III satisfactory results and is eligible for commercial milestones along with royalties. The transaction is expected to close in Q2’21
- Biogen to get exclusive regulatory- manufacturing- and commercial rights of BAT1806 in all countries excluding China (includes Hong Kong- Macau- and Taiwan)
- Biogen will expand its global biosimilars footprint with the potential approval of BAT1806 is a P-III clinical stage IL-6 receptor mAb that is a proposed biosimilar referencing Actemra (tocilizumab)
Ref: GlobeNewswire | Image: Seeking Alpha
Click here to read the full press release
Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com
